dabigatran has been researched along with Lung Neoplasms in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Bachmann, A; Becker, A; Biedert, H; Bytyqi, A; Heuer, J; Hirt, S; Krebs-Brown, A; Lüpfert, C; Perrin, D; Strotmann, R; Vetter, C; Yalkinoglu, Ö | 1 |
| Al-Samkari, H; Connors, JM | 1 |
| Chernick, M; DeFeo, K; Gilmour, SK; Hayes, C; Ryn, JV | 1 |
3 other study(ies) available for dabigatran and Lung Neoplasms
| Article | Year |
|---|---|
Assessment of the potential of the MET inhibitor tepotinib to affect the pharmacokinetics of CYP3A4 and P-gp substrates.
Topics: ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caco-2 Cells; Carcinoma, Non-Small-Cell Lung; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dabigatran; Drug Interactions; Humans; Lung Neoplasms; Midazolam | 2023 |
Dual anticoagulation with fondaparinux and dabigatran for treatment of cancer-associated hypercoagulability.
Topics: Adult; Anticoagulants; Antithrombins; Dabigatran; Drug Therapy, Combination; Factor Xa Inhibitors; Fondaparinux; Humans; Lung Neoplasms; Male; Recurrence; Thrombophilia; Thrombosis; Venous Thromboembolism | 2018 |
Use of dabigatran etexilate to reduce breast cancer progression.
Topics: Animals; Antithrombin Proteins; Benzimidazoles; Breast Neoplasms; Cell Adhesion; Cell Movement; Cells, Cultured; Dabigatran; Disease Progression; Humans; Immunoenzyme Techniques; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; NIH 3T3 Cells; Pyridines; Rats; Thrombin; Trachea | 2010 |